-
Something wrong with this record ?
Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
M. Svaton, M. Zemanova, J. Skrickova, L. Jakubikova, V. Kolek, J. Kultan, L. Koubkova, A. Bejckova, F. Salajka, M. Hrnciarik, B. Melichar, D. Vrana, M. Konecny, R. Chloupkova, M. Pesek,
Language English Country Greece
Document type Journal Article
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
- MeSH
- Survival Analysis MeSH
- Chronic Disease MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Lung Neoplasms complications diagnosis drug therapy mortality MeSH
- Carcinoma, Non-Small-Cell Lung complications diagnosis drug therapy mortality MeSH
- Nivolumab therapeutic use MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Aged MeSH
- Inflammation complications diagnosis mortality MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
AIM: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. CONCLUSION: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment.
Department of Oncology Charles University 1st Faculty of Medicine Prague Prague Czech Republic
Department of Oncology Palacky University Faculty of Medicine and Dentistry Olomouc Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012080
- 003
- CZ-PrNML
- 005
- 20190424143941.0
- 007
- ta
- 008
- 190405s2018 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.13048 $2 doi
- 035 __
- $a (PubMed)30504389
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Svaton, Martin $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic svatonm@fnplzen.cz.
- 245 10
- $a Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer / $c M. Svaton, M. Zemanova, J. Skrickova, L. Jakubikova, V. Kolek, J. Kultan, L. Koubkova, A. Bejckova, F. Salajka, M. Hrnciarik, B. Melichar, D. Vrana, M. Konecny, R. Chloupkova, M. Pesek,
- 520 9_
- $a AIM: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. CONCLUSION: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nemalobuněčný karcinom plic $x komplikace $x diagnóza $x farmakoterapie $x mortalita $7 D002289
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x komplikace $x diagnóza $x mortalita $7 D007249
- 650 _2
- $a nádory plic $x komplikace $x diagnóza $x farmakoterapie $x mortalita $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nivolumab $x terapeutické užití $7 D000077594
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a analýza přežití $7 D016019
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zemanova, Milada $u Department of Oncology, Charles University, First Faculty of Medicine in Prague, Prague, Czech Republic.
- 700 1_
- $a Skrickova, Jana $u Department of Respiratory Diseases and TB, Faculty of Medicine, Masaryk University, and University Hospital, Brno, Czech Republic.
- 700 1_
- $a Jakubikova, Lenka $u Department of Respiratory Diseases and TB, Faculty of Medicine, Masaryk University, and University Hospital, Brno, Czech Republic.
- 700 1_
- $a Kolek, Vitezslav $u Department of Pneumology and Phthisiology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
- 700 1_
- $a Kultan, Juraj $u Department of Pneumology and Phthisiology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
- 700 1_
- $a Koubkova, Leona $u Department of Pneumology, Second Faculty of Medicine, Charles University Prague and Faculty Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Bejckova, Alzbeta $u Department of Pneumology, Second Faculty of Medicine, Charles University Prague and Faculty Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Salajka, Frantisek $u Department of Pneumology, Charles University, Faculty of Medicine in Hradec Kralove, Prague, Czech Republic.
- 700 1_
- $a Hrnciarik, Michal $u Department of Pneumology, Charles University, Faculty of Medicine in Hradec Kralove, Prague, Czech Republic.
- 700 1_
- $a Melichar, Bohuslav $u Department of Oncology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
- 700 1_
- $a Vrana, David $u Department of Oncology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
- 700 1_
- $a Konecny, Marek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Chloupková, Renata $7 xx0235127 $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Pesek, Milos $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 38, č. 12 (2018), s. 6771-6782
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30504389 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190424144020 $b ABA008
- 999 __
- $a ok $b bmc $g 1391390 $s 1050385
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 38 $c 12 $d 6771-6782 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20190405
